Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral
anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and …

Atrial fibrillation (AF) is the most prevalent arrhythmia among adults worldwide, frequently co-
occurring with comorbidities such as Heart Failure (HF) and Type 2 Diabetes Mellitus …

Introduction Gliflozins are recommended as first‐line treatment in patients with heart failure
and/or cardiovascular comorbidities and are demonstrated to reduce atrial fibrillation (AF) …

The global prevalence of diabetes mellitus (DM) has led to widespread multi-system
damage, especially in cardiovascular and renal functions, heightening morbidity and …

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and
approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic …

Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved
ejection fraction (HFpEF). Despite this combination being closely associated with …

Background Although the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) in
patients with obesity and heart failure with preserved ejection fraction (HFpEF) has …

We perused with heightened interest the study by Satti et al 1 in this issue of JACC: Clinical
Electrophysiology. The investigators leveraged data from the TriNetX research database to …

Sodium-glucose co-transporter 2 inhibitors (SGLT2is), primarily used for managing type 2
diabetes mellitus, have recently gained attention for their potential cardiovascular benefits …

Background Atrial fibrillation (AF) is a widespread type of sustained arrhythmia that poses
significant health risks. Catheter ablation is the preferred treatment; however, arrhythmia …